분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2007-08-07 12:12:14 , Hit : 4976
 Gene therapy trial on hold

2007.07.31

As the US Food and Drug Administration prepares to investigate the death of a patient in a phase I/II gene therapy trial for inflammatory arthritis, researchers in the field say the treatment's delivery vector, an adeno-associated virus (AAV), was unlikely to be the culprit.

"Vectors in this class have been used on hundreds of patients over the last 12 years, and are not associated with acute toxicity," said Terence Flotte of the University of Massachusetts Medical School in Worcester. Flotte has been a principal investigator in several clinical trials of AAV-based gene therapy, but is not associated with the trial in question. "I've never seen anything like this," he told The Scientist. "Whatever this is, it's unusual."

"The AAV vectors in themselves are unlikely to cause inflammation or cell damage," agreed Theodore Friedmann of the University of California, San Diego, previous president of the American Society of Gene Therapy. Although he cautioned against speculating in the absence of clinical data, Friedmann noted that the transgene the vector encoded could have caused the patient's reaction. "It's a powerful transgene," said Friedmann. "It might have induced a massive immune response of some sort."

Mark Kay of the Stanford University School of Medicine in Palo Alto, Calif., cited the excellent safety record adeno-associated viruses had both in animal and human studies. Kay, who has led trials that used these vectors, said however that in the present case he did not rule out the possibility of an acute immunological response to the AAV itself.

The FDA placed the trial on hold after the company sponsoring it, Targeted Genetics of Seattle, told the agency on July 20 that the patient had suffered a serious adverse event in response to the treatment. The patient died on July 24.

In the trial, the AAV vector delivered a transgene encoding the receptor for tumor necrosis factor (TNF)-alpha, a cytokine that causes joint swelling in arthritis patients. The receptor, secreted by the target cells, binds to TNF-alpha, to reduce inflammation and protect the joint.

Usually prescribed for autoimmune conditions such as rheumatoid arthritis, the TNF-alpha receptor works by suppressing the immune system. But the protein could also have opened the door to an infection, suggested Flotte.

According to a July 28 article in the Washington Post, the trial had raised safety concerns when it was proposed in 2003, including the fear that the viruses might spread from the joint to the whole body. Reviewers appointed by the National Institutes of Health's Recombinant DNA Activities Committee also questioned the usefulness of the study, since animal data had showed only a limited value for the therapy. However, the trial was eventually approved and progressed without serious side effects, according to a company official quoted by the Post.

In 1999, teenager Jesse Gelsinger died of multiple organ failure four days after getting gene therapy for a genetic liver disease. That vector, an adenovirus, was proved to be the direct cause of death. Since then, however, adenoviruses have been used in several trials without such incidents.

Adeno-associated viruses, also used in about a half-a-dozen ongoing gene therapy clinical trials, are thought to be safer than adenoviruses or retroviruses because they lack viral coding sequences in their genome and do not replicate.

Since the trial started in October 2005, 127 patients have received an initial injection of either the active drug or the placebo, according to Targeted Genetics. The patient's death came after getting a second injection, which contained the active drug, but the company has not disclosed whether his or her first injection was an active dose or a placebo...








1107   피부 세포를 배아 줄기세포로 만드는 방법  관리자 2007/06/11 3637
1106   시험관에서 혈관이 모방되었다?  관리자 2007/06/11 4118
1105   항암제를 암에 전달하는 새로운 나노물질  관리자 2007/06/11 4415
1104   뇌질환 치료제 delivery system 개발  관리자 2007/06/20 4167
1103   기존 HIV 발병 이론이 잘못되었다는 연구결과  이성욱 2007/06/27 4808
1102   HIV 치료에 효과가 기대되는 효소  이성욱 2007/07/02 4161
1101   암 백신 임상시험에 대한 새로운 관점  이성욱 2007/07/06 4613
1100   「프리온병」억제 물질 발견  관리자 2007/07/07 3929
1099   DNA에 전류 존재 확인- 마이크로 전자 디바이스 개발에 길  관리자 2007/07/07 4038
1098   새로운 췌장암 표적 발견  관리자 2007/07/07 3898
1097   새로운 폐암 발생 원인 유전자 발견  이성욱 2007/07/17 4889
1096   HIV가 어떻게 세포 분할에 관여하는 가에 대한 발견  이성욱 2007/07/20 5409
1095   질병으로 졸리는 이유  이성욱 2007/07/20 5248
1094   노화에도 효과를 보인 p53 항암 단백질  이성욱 2007/07/23 4857
1093   유전 정보를 편집하는 「Splicing」을 저해하는 물질 발견  이성욱 2007/07/25 5398
1092   miRNA와 Ago2에 의한 혈구세포의 발달과정 규명  이성욱 2007/08/02 5753
  Gene therapy trial on hold  이성욱 2007/08/07 4976
1090   암 발생과 관련된 DNA 수선 기작에 대한 새로운 시각  이성욱 2007/08/10 5249
1089   초소형 핵폭탄으로 암 치료  관리자 2007/08/28 4068
1088   종양치료에 효과적인 축소된 크기의 항체  이성욱 2007/08/31 5435

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN